Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
Konstantinopoulos P, Liu J, Luo W, Krasner C, Ishizuka J, Gockley A, Buss M, Campos S, Stover E, Wright A, Growdon W, Curtis J, Peralta A, Basada P, Quinn R, Gray K, Penson R, Cannistra S, Fleming G, Matulonis U. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). Journal Of Clinical Oncology 2019, 37: 5502-5502. DOI: 10.1200/jco.2019.37.15_suppl.5502.Peer-Reviewed Original ResearchEndometrial cancerObjective responseMicrosatellite InstablePrior therapyPD-L1 negative tumorsProgression-free survival ratesPersistent endometrial cancerPhase 2 studyPD-L1 inhibitorsCo-primary endpointsG3 toxicityG5 toxicityMeasurable diseasePrimary endpointProtocol therapyUnacceptable toxicityPD-L1Negative tumorsImmunohistochemical lossIHC expressionEligibility criteriaMismatch repair proteinsSurvival rateMSS statusCohort